Is LONA or ZNTL more profitable?

Zentalis Pharmaceuticals' return on equity of -53.61% beat Athira Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Athira Pharma N/A -381.01% -225.74% Zentalis Pharmaceuticals N/A -53.61% -40.67%

Which has better earnings & valuation, LONA or ELDN?

Eledon Pharmaceuticals is trading at a lower price-to-earnings ratio than Athira Pharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Athira Pharma N/A N/A -$105.61M -$5.21 N/A Eledon Pharmaceuticals N/A N/A -$45.62M -$0.77 N/A

Is LONA or ELDN more profitable?

Eledon Pharmaceuticals' return on equity of -116.97% beat Athira Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Athira Pharma N/A -381.01% -225.74% Eledon Pharmaceuticals N/A -116.97% -41.91%

Which has preferable valuation and earnings, LONA or NMRA?

Athira Pharma is trading at a lower price-to-earnings ratio than Neumora Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Athira Pharma N/A N/A -$105.61M -$5.21 N/A Neumora Therapeutics N/A N/A -$236.93M -$1.33 N/A

Is LONA or NMRA more profitable?

Neumora Therapeutics' return on equity of -181.70% beat Athira Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Athira Pharma N/A -381.01% -225.74% Neumora Therapeutics N/A -181.70% -119.15%

Athira Pharma (LONA) Competitors

$8.87 0.00 (0.00%)

Closing price 07/2/2026 04:00 PM Eastern

Extended Trading

$8.83 -0.04 (-0.45%)

As of 07/2/2026 07:20 PM Eastern

Compare

LONA vs. ORGO, ZNTL, LYEL, ELDN, and NMRA

Should you buy Athira Pharma stock or one of its competitors? MarketBeat compares Athira Pharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Athira Pharma include Organogenesis (ORGO), Zentalis Pharmaceuticals (ZNTL), Lyell Immunopharma (LYEL), Eledon Pharmaceuticals (ELDN), and Neumora Therapeutics (NMRA). These companies are all part of the "pharmaceutical products" industry.

How does Athira Pharma compare to Organogenesis?

Organogenesis (NASDAQ:ORGO) and Athira Pharma (NASDAQ:LONA) are both small-cap pharmaceutical products companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, institutional ownership, valuation, earnings, dividends and media sentiment.

Organogenesis has higher revenue and earnings than Athira Pharma. Organogenesis is trading at a lower price-to-earnings ratio than Athira Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Organogenesis	$512.59M	0.59	$37.03M	-$0.19	N/A
Athira Pharma	N/A	N/A	-$105.61M	-$5.21	N/A

Athira Pharma has a net margin of 0.00% compared to Organogenesis' net margin of -0.84%. Organogenesis' return on equity of 9.63% beat Athira Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Organogenesis	-0.84%	9.63%	4.76%
Athira Pharma	N/A	-381.01%	-225.74%

49.6% of Organogenesis shares are owned by institutional investors. Comparatively, 57.1% of Athira Pharma shares are owned by institutional investors. 18.8% of Organogenesis shares are owned by insiders. Comparatively, 25.7% of Athira Pharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Organogenesis has a beta of 1.33, meaning that its share price is 33% more volatile than the broader market. Comparatively, Athira Pharma has a beta of 2.01, meaning that its share price is 101% more volatile than the broader market.

In the previous week, Organogenesis' average media sentiment score of 0.00 equaled Athira Pharma'saverage media sentiment score.

Company	Overall Sentiment
Organogenesis	Neutral
Athira Pharma	Neutral

Organogenesis presently has a consensus price target of $5.75, indicating a potential upside of 143.64%. Athira Pharma has a consensus price target of $15.00, indicating a potential upside of 69.11%. Given Organogenesis' higher possible upside, research analysts clearly believe Organogenesis is more favorable than Athira Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Organogenesis	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Athira Pharma	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Summary

Athira Pharma beats Organogenesis on 7 of the 13 factors compared between the two stocks.

How does Athira Pharma compare to Zentalis Pharmaceuticals?

Athira Pharma (NASDAQ:LONA) and Zentalis Pharmaceuticals (NASDAQ:ZNTL) are both small-cap pharmaceutical products companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, earnings, profitability, media sentiment, institutional ownership, dividends and analyst recommendations.

In the previous week, Zentalis Pharmaceuticals had 1 more articles in the media than Athira Pharma. MarketBeat recorded 1 mentions for Zentalis Pharmaceuticals and 0 mentions for Athira Pharma. Athira Pharma's average media sentiment score of 0.00 equaled Zentalis Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Athira Pharma	Neutral
Zentalis Pharmaceuticals	Neutral

57.1% of Athira Pharma shares are owned by institutional investors. 25.7% of Athira Pharma shares are owned by insiders. Comparatively, 3.8% of Zentalis Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Athira Pharma has a beta of 2.01, suggesting that its share price is 101% more volatile than the broader market. Comparatively, Zentalis Pharmaceuticals has a beta of 1.92, suggesting that its share price is 92% more volatile than the broader market.

Athira Pharma has higher earnings, but lower revenue than Zentalis Pharmaceuticals. Zentalis Pharmaceuticals is trading at a lower price-to-earnings ratio than Athira Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Athira Pharma	N/A	N/A	-$105.61M	-$5.21	N/A
Zentalis Pharmaceuticals	$67.43M	4.71	-$137.06M	-$1.73	N/A

Athira Pharma currently has a consensus price target of $15.00, suggesting a potential upside of 69.11%. Zentalis Pharmaceuticals has a consensus price target of $5.83, suggesting a potential upside of 30.79%. Given Athira Pharma's stronger consensus rating and higher probable upside, equities analysts clearly believe Athira Pharma is more favorable than Zentalis Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Athira Pharma	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Zentalis Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14

Zentalis Pharmaceuticals' return on equity of -53.61% beat Athira Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Athira Pharma	N/A	-381.01%	-225.74%
Zentalis Pharmaceuticals	N/A	-53.61%	-40.67%

Summary

Athira Pharma beats Zentalis Pharmaceuticals on 8 of the 13 factors compared between the two stocks.

How does Athira Pharma compare to Lyell Immunopharma?

Athira Pharma (NASDAQ:LONA) and Lyell Immunopharma (NASDAQ:LYEL) are both small-cap pharmaceutical products companies, but which is the better business? We will compare the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, earnings, dividends, profitability and analyst recommendations.

Athira Pharma presently has a consensus target price of $15.00, suggesting a potential upside of 69.11%. Lyell Immunopharma has a consensus target price of $43.00, suggesting a potential upside of 206.05%. Given Lyell Immunopharma's stronger consensus rating and higher probable upside, analysts clearly believe Lyell Immunopharma is more favorable than Athira Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Athira Pharma	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Lyell Immunopharma	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

Athira Pharma has higher earnings, but lower revenue than Lyell Immunopharma. Athira Pharma is trading at a lower price-to-earnings ratio than Lyell Immunopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Athira Pharma	N/A	N/A	-$105.61M	-$5.21	N/A
Lyell Immunopharma	$40K	8,194.66	-$274.45M	-$13.80	N/A

Athira Pharma has a beta of 2.01, indicating that its share price is 101% more volatile than the broader market. Comparatively, Lyell Immunopharma has a beta of -0.06, indicating that its share price is 106% less volatile than the broader market.

Athira Pharma has a net margin of 0.00% compared to Lyell Immunopharma's net margin of -794,858.12%. Lyell Immunopharma's return on equity of -85.71% beat Athira Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Athira Pharma	N/A	-381.01%	-225.74%
Lyell Immunopharma	-794,858.12%	-85.71%	-66.41%

In the previous week, Lyell Immunopharma's average media sentiment score of 1.00 beat Athira Pharma's score of 0.00 indicating that Lyell Immunopharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Athira Pharma	Neutral
Lyell Immunopharma	Positive

57.1% of Athira Pharma shares are held by institutional investors. Comparatively, 66.1% of Lyell Immunopharma shares are held by institutional investors. 25.7% of Athira Pharma shares are held by insiders. Comparatively, 6.2% of Lyell Immunopharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Lyell Immunopharma beats Athira Pharma on 10 of the 15 factors compared between the two stocks.

How does Athira Pharma compare to Eledon Pharmaceuticals?

Athira Pharma (NASDAQ:LONA) and Eledon Pharmaceuticals (NASDAQ:ELDN) are both small-cap pharmaceutical products companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, valuation, dividends, profitability, risk, earnings, analyst recommendations and institutional ownership.

Eledon Pharmaceuticals' return on equity of -116.97% beat Athira Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Athira Pharma	N/A	-381.01%	-225.74%
Eledon Pharmaceuticals	N/A	-116.97%	-41.91%

In the previous week, Athira Pharma's average media sentiment score of 0.00 equaled Eledon Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Athira Pharma	Neutral
Eledon Pharmaceuticals	Neutral

Athira Pharma has a beta of 2.01, meaning that its share price is 101% more volatile than the broader market. Comparatively, Eledon Pharmaceuticals has a beta of 0.95, meaning that its share price is 5% less volatile than the broader market.

Eledon Pharmaceuticals is trading at a lower price-to-earnings ratio than Athira Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Athira Pharma	N/A	N/A	-$105.61M	-$5.21	N/A
Eledon Pharmaceuticals	N/A	N/A	-$45.62M	-$0.77	N/A

Athira Pharma presently has a consensus price target of $15.00, suggesting a potential upside of 69.11%. Eledon Pharmaceuticals has a consensus price target of $9.67, suggesting a potential upside of 144.73%. Given Eledon Pharmaceuticals' higher possible upside, analysts plainly believe Eledon Pharmaceuticals is more favorable than Athira Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Athira Pharma	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Eledon Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

57.1% of Athira Pharma shares are owned by institutional investors. Comparatively, 56.8% of Eledon Pharmaceuticals shares are owned by institutional investors. 25.7% of Athira Pharma shares are owned by insiders. Comparatively, 9.6% of Eledon Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Eledon Pharmaceuticals beats Athira Pharma on 5 of the 9 factors compared between the two stocks.

How does Athira Pharma compare to Neumora Therapeutics?

Athira Pharma (NASDAQ:LONA) and Neumora Therapeutics (NASDAQ:NMRA) are both small-cap pharmaceutical products companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, profitability, dividends, institutional ownership, valuation, analyst recommendations, risk and media sentiment.

Athira Pharma is trading at a lower price-to-earnings ratio than Neumora Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Athira Pharma	N/A	N/A	-$105.61M	-$5.21	N/A
Neumora Therapeutics	N/A	N/A	-$236.93M	-$1.33	N/A

Neumora Therapeutics' return on equity of -181.70% beat Athira Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Athira Pharma	N/A	-381.01%	-225.74%
Neumora Therapeutics	N/A	-181.70%	-119.15%

Athira Pharma has a beta of 2.01, suggesting that its share price is 101% more volatile than the broader market. Comparatively, Neumora Therapeutics has a beta of 2.74, suggesting that its share price is 174% more volatile than the broader market.

In the previous week, Athira Pharma's average media sentiment score of 0.00 equaled Neumora Therapeutics'average media sentiment score.

Company	Overall Sentiment
Athira Pharma	Neutral
Neumora Therapeutics	Neutral

57.1% of Athira Pharma shares are owned by institutional investors. Comparatively, 47.7% of Neumora Therapeutics shares are owned by institutional investors. 25.7% of Athira Pharma shares are owned by insiders. Comparatively, 26.9% of Neumora Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Athira Pharma presently has a consensus target price of $15.00, suggesting a potential upside of 69.11%. Neumora Therapeutics has a consensus target price of $6.86, suggesting a potential upside of 310.61%. Given Neumora Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Neumora Therapeutics is more favorable than Athira Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Athira Pharma	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Neumora Therapeutics	2 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.60

Summary

Neumora Therapeutics beats Athira Pharma on 10 of the 12 factors compared between the two stocks.

Get Athira Pharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LONA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LONA vs. The Competition

Export

Metric	Athira Pharma	Biological Products, Except Diagnostic Substances Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$83.32M	$538.08M	$5.20B	$12.48B
Dividend Yield	N/A	N/A	16.11%	6.52%
P/E Ratio	-1.70	N/A	23.91	24.70
Price / Sales	N/A	388.95	216.83	99.49
Price / Cash	N/A	N/A	35.06	57.09
Price / Book	2.98	2.94	13.25	6.46
Net Income	-$105.61M	-$81.71M	$113.80M	$337.01M
7 Day Performance	-5.64%	7.17%	0.93%	1.69%
1 Month Performance	7.91%	21.82%	1.08%	3.81%
1 Year Performance	N/A	-72.26%	10.03%	23.90%

Athira Pharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LONA Athira Pharma	3.5842 of 5 stars	$8.87 flat	$15.00 +69.1%	N/A	$83.32M	N/A	N/A	40
ORGO Organogenesis	1.8098 of 5 stars	$2.36 -3.3%	$5.75 +143.6%	-45.7%	$313.97M	$564.17M	N/A	950	Positive News
ZNTL Zentalis Pharmaceuticals	2.0493 of 5 stars	$4.46 +2.3%	$5.83 +30.8%	+256.8%	$310.02M	N/A	N/A	160
LYEL Lyell Immunopharma	3.7531 of 5 stars	$14.05 +8.3%	$43.00 +206.0%	+49.2%	$302.64M	$40K	N/A	270	Positive News Gap Down
ELDN Eledon Pharmaceuticals	1.4079 of 5 stars	$3.95 +1.3%	$9.67 +144.7%	+31.4%	$301.03M	N/A	N/A	10	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LONA) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Athira Pharma (LONA) Competitors

LONA vs. ORGO, ZNTL, LYEL, ELDN, and NMRA

How does Athira Pharma compare to Organogenesis?

Summary

How does Athira Pharma compare to Zentalis Pharmaceuticals?

Summary

How does Athira Pharma compare to Lyell Immunopharma?

Summary

How does Athira Pharma compare to Eledon Pharmaceuticals?

Summary

How does Athira Pharma compare to Neumora Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LONA vs. The Competition

Athira Pharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Athira Pharma (LONA) Competitors

LONA vs. ORGO, ZNTL, LYEL, ELDN, and NMRA

How does Athira Pharma compare to Organogenesis?

Which has better earnings and valuation, ORGO or LONA?

Is ORGO or LONA more profitable?

Do insiders & institutionals believe in ORGO or LONA?

Which has more volatility and risk, ORGO or LONA?

Does the media prefer ORGO or LONA?

Do analysts recommend ORGO or LONA?

Summary

How does Athira Pharma compare to Zentalis Pharmaceuticals?

Does the media favor LONA or ZNTL?

Do insiders and institutionals hold more shares of LONA or ZNTL?

Which has more volatility and risk, LONA or ZNTL?

Which has preferable earnings & valuation, LONA or ZNTL?

Do analysts rate LONA or ZNTL?

Is LONA or ZNTL more profitable?

Summary

How does Athira Pharma compare to Lyell Immunopharma?

Do analysts recommend LONA or LYEL?

Which has better earnings & valuation, LONA or LYEL?

Which has more risk and volatility, LONA or LYEL?

Is LONA or LYEL more profitable?

Does the media refer more to LONA or LYEL?

Do insiders & institutionals hold more shares of LONA or LYEL?

Summary

How does Athira Pharma compare to Eledon Pharmaceuticals?

Is LONA or ELDN more profitable?

Does the media prefer LONA or ELDN?

Which has more risk & volatility, LONA or ELDN?

Which has better earnings & valuation, LONA or ELDN?

Do analysts recommend LONA or ELDN?

Do insiders and institutionals hold more shares of LONA or ELDN?

Summary

How does Athira Pharma compare to Neumora Therapeutics?

Which has preferable valuation and earnings, LONA or NMRA?

Is LONA or NMRA more profitable?

Which has more volatility and risk, LONA or NMRA?

Does the media favor LONA or NMRA?

Do institutionals & insiders hold more shares of LONA or NMRA?

Do analysts rate LONA or NMRA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LONA vs. The Competition

Athira Pharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools